Knowledge Centers

Researchers at Stanford are working to develop a single-dose vaccine for SARS-CoV-2 that could potentially be stored at room temperature.

Chemistry Professor Carolyn Bertozzi says recruiting world-class scientists and engineers and developing ChEM-H into a hub where doctors and researchers can come together.

Researchers are pursuing antiviral drugs with broad efficacy against enteroviruses, which cause common colds and polio, and coronaviruses including the one that causes COVID

Stanford’s new IMA arose before the COVID-19 pandemic struck, but now its programs are focused entirely on helping faculty generate and test new medicines to slow the spread.

An effort to thwart viral diseases like hepatitis or the common cold led to a new collaboration and a novel class of cancer drugs that appears effective in mice.

Immunotherapy has great promise as a cancer treatment, but current therapies only work in some. Researchers found that microorganisms in our guts might be the deciding factor.

Justin Annes, MD, PhD, assistant professor of endocrinology, gerontology and metabolism, feels that he owes a great deal of credit for his unique research program to the ChEM-H

By delivering a drug directly to beta cells, researchers may be able to spur insulin production and potentially develop a diabetes therapy in the future.

To treat diabetes directly, doctors need a way to get drugs to cells that produce insulin. The key, Stanford researchers report, may be those cells’ affinity for zinc.

Tracing the genetic process through which parakeets produce either yellow or blue feathers has given Stanford scientists insights that could uncover other biochemical pathways.

Physician-scientist Justin Annes specializes in a rare type of tumor disorders. He shares his story, and interests, in this Stars of Stanford Medicine Q&A.

Macromolecular Structure Knowledge Center to help researchers who lack equipment for testing different crystallization conditions or expertise in working with challenging molecules

Creating a molecular snapshot of the way proteins interact could help development of new cancer drugs.

When molecules won't crystallize and technology confounds, who you gonna call?

Jeffrey Glenn, MD, PhD, is leading a new center to develop antiviral therapies that target the host cell instead of the virus.